Gynecologic Oncology Reports最新文献

{"title":"Embryonal rhabdomyosarcoma of the uterine corpus in a postmenopausal Woman: A case report and literature Review","authors":"Misako Omuro ,&nbsp;Yuichi Imai ,&nbsp;Yuki Ogawara ,&nbsp;Taichi Mizushima ,&nbsp;Erika Muraoka ,&nbsp;Shoji Yamanaka ,&nbsp;Satoshi Fujii ,&nbsp;Etsuko Miyagi","doi":"10.1016/j.gore.2025.101937","DOIUrl":"10.1016/j.gore.2025.101937","url":null,"abstract":"<div><h3>Background</h3><div>Rhabdomyosarcoma (RMS) is a rare malignant mesenchymal tumor, primarily affecting children. Occurrence in the uterine corpus of adults, particularly postmenopausal women, is extremely uncommon.</div></div><div><h3>Case Presentation</h3><div>A 60-year-old postmenopausal nulligravid woman presented with abnormal genital bleeding for three months. Pelvic examination revealed a friable mass extending from the uterine corpus. Biopsy confirmed embryonal RMS. She underwent modified radical hysterectomy with bilateral salpingo-oophorectomy for complete surgical resection. One cycle of adjuvant VAC chemotherapy (vincristine, actinomycin D, and cyclophosphamide) was administered but discontinued at her request. No residual disease was observed postoperatively, and she remains disease-free 12 months after surgery.</div></div><div><h3>Conclusion</h3><div>Adult-onset uterine corpus embryonal RMS is rare, and standardized treatment protocols are lacking. Early diagnosis, complete surgical resection, and individualized therapy are essential. A literature review highlights clinical characteristics, treatment strategies, and prognostic considerations.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101937"},"PeriodicalIF":1.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of significant pleural effusion at ovarian cancer diagnosis: Outcomes of triage to neoadjuvant chemotherapy without thoracic assessment","authors":"Stuart A. Ostby ,&nbsp;Chiara Ainio ,&nbsp;Conway Xu ,&nbsp;Kelly H. Bruce ,&nbsp;Matthew S. Block ,&nbsp;William A. Cliby ,&nbsp;Amanika Kumar ,&nbsp;Carrie L. Langstraat","doi":"10.1016/j.gore.2025.101944","DOIUrl":"10.1016/j.gore.2025.101944","url":null,"abstract":"<div><h3>Objectives</h3><div>Management of epithelial ovarian cancer presenting with moderate to large pleural effusion at first diagnosis is a clinical challenge. Several options are utilized with limited evidence including initial thoracoscopic evaluation, neoadjuvant chemotherapy (NACT) or some combination. We sought to evaluate the disease course and patterns of recurrence after triage to NACT.</div></div><div><h3>Methods</h3><div>We included all clinical Stage IVA patients having moderate to large pleural effusions without radiologic evidence of a Stage IVB metastasis presenting to our institution between 2016 and 2021. Clinical outcomes and patterns of recurrence were evaluated using descriptive statistics and Kaplan-Meier curves.</div></div><div><h3>Results</h3><div>There were 31 patients (7.5 % of new ovarian cancer cases) who met inclusion criteria with median age 68.0 years. Most had high grade serous histology (29; 93.5 %) and 3/27 (11.1 %) were BRCA positive. Factors influencing triage to NACT were effusion alone in 3 (9.7 %) patients whereas 14/31 (45.2 %) had ≥2 factors. Resolution of the effusion occurred after NACT alone in 23 (74.2 %). Eight patients never proceeded to surgery. Complete gross resection (CGR) of abdominal disease at interval debulking surgery (IDS) was achieved in 14/23 (60.9 %), residual disease (RD) ≤1 cm in 8/23 (34.8 %) and &gt;1 cm in 1/23 (4.3 %). Chemotherapy response scores were available for 19/23 cases and did not correlate with survival. After IDS, all patients received adjuvant platinum-based chemotherapy for a median of 3 cycles and 4 patients received maintenance therapy (PARP inhibitor in 4, bevacizumab in 1). Median OS for the whole cohort was 30.5 months: 3-year OS was 0 % if no surgery (8 patients), 27.8 % if any visible disease after IDS (9 patients), and 71.4 % if CGR (5-year OS 64.3 %). Recurrence or progression occurred in 30/31 distributed as follows: abdomen alone (16/30, 53.3 %) versus abdomen and thorax (13/30, 41.9 %). Only 1 patient recurred in the thorax alone.</div></div><div><h3>Conclusions</h3><div>Limited evidence directs the best management for patients presenting with clinical Stage IVA disease. Our data represent a particularly high-risk subgroup which may be characteristic of patients with large pleural effusions and adds important information showing that approximately half of these patients have ≥2 indications to favor NACT, signifying their high-risk status. Despite this, when CGR in the abdomen was achieved at IDS, median OS was greater than 5 years.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101944"},"PeriodicalIF":1.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145003908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe hemorrhage in choriocarcinoma: three scenarios and treatment strategies","authors":"J. Altmann,&nbsp;D. Dimitrova,&nbsp;J. Sehouli","doi":"10.1016/j.gore.2025.101930","DOIUrl":"10.1016/j.gore.2025.101930","url":null,"abstract":"<div><h3>Introduction</h3><div>Massive hemorrhage originating from the primary tumor site or metastases is a feared complication of choriocarcinoma. We present three cases of severe hemorrhage in patients with gestational choriocarcinoma and their clinical management.</div></div><div><h3>Case series</h3><div>The first case is a 27-year old woman, who presented with acute hepatic hemorrhage due to metastases of choriocarcinoma 5 months after the birth of her first child. After abdominal packing via laparotomy and transfer of the patient in stable condition to our intensive care unit embolization of several hepatic arteries was performed by interventional angiography. The second case, a 28-year old primipara, presented with hemoperitoneum as a result of uterus perforation by choriocarcinoma. Surgical sutures of the perforated lesion were applied via laparotomy, preserving the uterus. The third case is a 28-year old primigravida with massive vaginal hemorrhage of a choriocarcinoma with pulmonary metastases. Stabilization of the bleeding was achieved by embolization of uterine arteries.</div><div>All patients were classified as high-risk (FIGO classification) gestational choriocarcinoma and received EMA/CO chemotherapy until ßHCG reached normal levels as well as up to three additional cycles as consolidation. To date, all patients are in remission.</div></div><div><h3>Conclusion</h3><div>In case of severe hemorrhage in patients with choriocarcinoma a skilled interdisciplinary team is needed. In case of acute hemorrhage in choriocarcinoma embolization of arteries should be preferred since these are safe and effective measures. In the vast majority of cases fertility-preserving strategies can safely be applied. Hysterectomy is not recommended as first-line treatment.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101930"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145019715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape of genomic alterations and clinical outcomes in low-grade serous ovarian cancer in Korea","authors":"Yu-Seon Shim ,&nbsp;Ji Hyun Kim ,&nbsp;Sang-soo Seo ,&nbsp;Sokbom Kang ,&nbsp;Sang-Yoon Park ,&nbsp;Myong Cheol Lim","doi":"10.1016/j.gore.2025.101934","DOIUrl":"10.1016/j.gore.2025.101934","url":null,"abstract":"<div><h3>Introduction</h3><div>To investigate the clinical characteristics, molecular findings, and survival outcomes of patients with low-grade serous ovarian cancer in Korea, with a focus on addressing the limited data on genetic profiling and targeted therapies in Asian populations.</div></div><div><h3>Methods</h3><div>This study is a retrospective review of patients with pathologically confirmed LGSOC treated at the National Cancer Center Korea between 2010 and 2023. Patients underwent cytoreductive surgery and/or systemic or hormonal therapy. Molecular profiling included next-generation sequencing (NGS) of formalin-fixed, paraffin-embedded tumor samples and homologous recombination deficiency (HRD) testing. Survival outcomes were assessed using Kaplan–Meier analysis.</div></div><div><h3>Results</h3><div>A total of 62 patients were included, with a median age of 41 years; 61.3 % presented with advanced-stage disease. BRCA mutations were detected in 6.4 % (<em>BRCA1</em>: 4.8 %, <em>BRCA2</em>: 1.6 %). MAPK pathway alterations were identified in <em>KRAS</em> (11.3 %), <em>BRAF</em> (9.7 %), <em>NF1</em> (3.7 %), and <em>NRAS</em> (1.2 %). Among <em>BRAF</em> mutations, 66.7 % were V600E, while KRAS mutations predominantly involved codon 12. ER and PR were positive in 88.7 % and 66.1 % of cases, respectively. With a median follow-up of 47.5 months, the median progression-free survival (PFS) was 169.3 months (95 % CI: 60.6–NA).</div></div><div><h3>Conclusion</h3><div>This study identifies frequent MAPK pathway mutations, including <em>KRAS</em> and <em>BRAF</em>, and a prevalence of <em>BRCA1/2</em> mutations in low-grade serous ovarian cancer. Compared to Western cohorts, <em>KRAS</em> and <em>BRAF</em> mutations were observed at relatively lower frequencies, highlighting potential regional differences in the molecular landscape of low-grade serous ovarian cancer.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101934"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144988118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant Brenner tumor with extensive clear cell features: A valuable diagnostic lesson learned from molecular tumor profiling and AI-based tumor differential tool","authors":"John A Steinharter ,&nbsp;Corinne Jansen ,&nbsp;Hassan Ghani ,&nbsp;Apsra Nasir ,&nbsp;Marzia Capelletti ,&nbsp;Ashley Stuckey ,&nbsp;M.Ruhul Quddus ,&nbsp;Yun-An Tseng","doi":"10.1016/j.gore.2025.101939","DOIUrl":"10.1016/j.gore.2025.101939","url":null,"abstract":"<div><h3>Background</h3><div>Malignant Brenner tumor (MBT) with extensive clear cell features mimicking an ovarian clear cell carcinoma (CCC) is exceedingly rare. This case report discusses the diagnostic challenges associated with this unusual histologic finding and highlights the value of molecular tumor profiling and artificial intelligence (AI)-based tools in tumor diagnostics.</div></div><div><h3>Case Summary</h3><div>A 55-year-old woman presented with a 17.7 cm complex left ovarian mass, which was initially diagnosed as ovarian clear cell carcinoma on the frozen and permanent H&amp;E sections. The subsequent next-generation sequencing (NGS) and an AI-based tumor differential tool predicted an 88 % match of urothelial origin for the ovarian tumor driven by strong expression of GATA3, uroplakin 2, and AMACR, while assigning 0 % match to ovarian CCC. The molecular and histologic discordance prompted pathologic re-evaluation. On the additional sections submitted from the ovarian tumor, a small component of benign Brenner tumor was identified adjacent to the tumor with extensive clear cell features. In addition, both the tumor cells exhibiting clear cell features and the benign Brenner tumor showed positive expression of urothelial markers by immunohistochemistry. The diagnosis was amended to MBT with extensive clear cell features. The NGS data was reviewed and showed the ovarian tumor harbored CDKN2A/B loss and a molecular triple phenotype (MDM2 amplification/TP53 wild-type/TERT wild-type), supporting the diagnosis of MBT and disfavoring metastatic urothelial carcinoma.</div></div><div><h3>Conclusion</h3><div>MBT should be considered in the differential diagnosis of ovarian neoplasms with clear cell features. Extensive tumor sampling combined with careful evaluation of the histologic and immunohistochemical features and molecular analysis is the key to accurate diagnosis. AI-based tumor differential tools are valuable adjuncts to tumor diagnostics when investigated with other pathological and clinical findings.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101939"},"PeriodicalIF":1.3,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144996724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of a stepwise process for somatic testing in patients with a new diagnosis of germline negative epithelial ovarian cancer","authors":"Casey L. Lawler ,&nbsp;Sara M. Klennert ,&nbsp;Kristin C. Cole ,&nbsp;Karen S. Schaepe ,&nbsp;Laura J. Ongie ,&nbsp;Megan E. Grudem ,&nbsp;Carolyn M. Klampe ,&nbsp;Myra J. Wick ,&nbsp;Vonda M. Wall ,&nbsp;Sanjna Rajput ,&nbsp;Clarissa L. Polen-De ,&nbsp;Amanika Kumar","doi":"10.1016/j.gore.2025.101935","DOIUrl":"10.1016/j.gore.2025.101935","url":null,"abstract":"<div><h3>Objective</h3><div>We sought to establish a process for increasing somatic tumor testing for patients with germline BRCA negative advanced stage epithelial ovarian cancer (EOC) and to gain insight into patients’ comprehension of their genetic testing.</div></div><div><h3>Methods</h3><div>A multidisciplinary team utilized quality improvement framework to address clinical needs. After implementation of a new somatic testing process, we compared the rates of genetic testing referral, germline testing and somatic testing recommendations between a historic cohort (January 1, 2019-June 20, 2019) and implementation cohort (October 1, 2020 – March 31, 2021). Patients diagnosed with stage III-IV EOC who underwent surgery were included for analysis. To explore patients’ comprehension of their genetic testing results, twenty-three patients in the historic cohort participated in semi-structured interviews.</div></div><div><h3>Results</h3><div>Patients with advanced stage EOC without a germline BRCA mutation received recommendations for somatic testing 53.5 % (23/43) of the time in the historic cohort. An improvement in the rate of somatic testing recommendations was seen in patients without a germline mutation in the implementation cohort (84.6 % [22/26], P = 0.010). There was no decrease in germline testing after implementation (90 % [63/70] and 96.3 % [52/54,] P = 0.30). Most patients (21/23) in the historic cohort were not aware that both germline and somatic testing were completed for their oncology care.</div></div><div><h3>Conclusion</h3><div>We successfully increased somatic testing recommendations in germline BRCA negative patients prior to completing upfront EOC treatment allowing for a timely, individualized discussion of maintenance PARP inhibitor use. Qualitative assessment of patients’ comprehension of genetic testing for EOC shows a deficit in patient knowledge.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101935"},"PeriodicalIF":1.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144931642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of racial differences in HER2 status and molecular subtype in grade 3 endometroid endometrial carcinoma","authors":"Sarah A. Ackroyd ,&nbsp;Gabrielle Sudilovsky ,&nbsp;Yan Che ,&nbsp;Jennifer A. Bennett ,&nbsp;S Diane Yamada ,&nbsp;Gini F Fleming","doi":"10.1016/j.gore.2025.101936","DOIUrl":"10.1016/j.gore.2025.101936","url":null,"abstract":"<div><h3>Objectives</h3><div>To characterize stage I-III Grade 3 endometroid endometrial cancer (Gr3 EEC) by molecular subtype and human epithelial growth factor receptor 2 (HER2) status and explore differences in characteristics by race.</div></div><div><h3>Methods</h3><div>We identified patients with a diagnosis of stage I-III Gr3 EEC from a single-institution health system cancer registry and pathologically confirmed the diagnosis. Review of the electronic health record was performed as needed to confirm patient characteristics. Next-generation sequencing (NGS) and immunohistochemical staining (IHC) for HER2 was performed on all primary tumors.</div></div><div><h3>Results</h3><div>Thirty-four primary cases remained classified as stage I-III Gr3 EEC after pathologic review and exclusion of cases lacking in-house primary tumor for re-review. Fifteen were categorized as microsatellite unstable (MSI; 44 %), 10 as copy number high (CNH; 29 %), six as polymerase E mutant (<em>POLE</em>mut; 17.6 %) and three as copy number low (CNL; 8.8 %). Thirteen patients were Black, 18 were White, and 3 had a race of “other and/or unknown”. HER2 status by IHC in the primary tumor was 0 (n = 7; 20.5 %), 1+ (n = 11; 32 %), 2+ (n = 14; 41 %), 3+ (n = 1; 3 %). There was no difference in the distribution of TCGA subtype or HER2 status by race.</div></div><div><h3>Conclusion</h3><div>In stage I-III stage Gr3 EEC HER2 positivity (3 + ) was uncommon, but expression at the 2 + level was frequent, and did not differ by race. In this limited sample, there were no differences in distribution of TCGA subtype amongst patients with grade 3 EEC. Other causes should be explored to explain reported differences in outcomes in EEC by race.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101936"},"PeriodicalIF":1.3,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): About three case reports","authors":"J. Benichou ,&nbsp;J. Varinot ,&nbsp;R. Bossi-Croci ,&nbsp;M. Bazot ,&nbsp;D. Sitbon ,&nbsp;M. Dahan ,&nbsp;C. Ferrier ,&nbsp;Y. Dabi ,&nbsp;C. Touboul ,&nbsp;J. Lotz ,&nbsp;E. Darai","doi":"10.1016/j.gore.2025.101932","DOIUrl":"10.1016/j.gore.2025.101932","url":null,"abstract":"<div><h3>Background</h3><div>Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive ovarian cancer affecting young women, typically associated with poor survival. We present three cases of SCCOHT and review the current literature regarding clinical features, diagnosis, management, and survival.</div></div><div><h3>Cases</h3><div>Three patients aged 16, 29, and 39 years were treated for ovarian masses. None presented with hypercalcemia. In case 1, MRI findings mimicked a mucinous cystadenocarcinoma, while the other two cases appeared as benign ovarian tumors. Following initial surgery and histological diagnosis of SCCOHT, all patients received comprehensive radical surgery, multi-agent chemotherapy, radiotherapy, and autologous stem cell transplantation. Two patients remain recurrence-free at 5 and 20 years, while the third has a 10-month follow-up. Genetic testing was performed in two patients, revealing no constitutional mutations in SMARCA4 or related genes.</div></div><div><h3>Conclusions</h3><div>These cases highlight the difficulty of establishing a preoperative diagnosis of SCCOHT. Unlike previous reports, our data suggest that intensive multimodal therapy can result in favourable outcomes for stage I SCCOHT. Further studies are needed to define optimal treatment strategies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101932"},"PeriodicalIF":1.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity management in the setting of endometrial cancer and hyperplasia: A narrative review","authors":"Natalie Moshayedi ,&nbsp;Kiran Clair ,&nbsp;Alex A. Francoeur","doi":"10.1016/j.gore.2025.101929","DOIUrl":"10.1016/j.gore.2025.101929","url":null,"abstract":"<div><div>Obesity is a well-established risk factor for endometrial cancer, driven by chronic inflammation, insulin resistance, and excess estrogen. As the global obesity epidemic continues to worsen, effective weight management plays a crucial role in reducing both incidence and progression. Recent pharmacotherapy advancements, particularly GLP-1 receptor agonists, show promising weight loss effects by modulating appetite and metabolism. Preclinical studies suggest these agents may also influence cancer progression, though further clinical research is needed. Bariatric surgery remains the most effective long-term intervention for severe obesity, offering significant metabolic and hormonal benefits. Weight loss surgery is associated with reduced cancer risk and improvements in molecular markers, though findings on specific biomarkers remain inconsistent. This narrative review explores emerging weight loss interventions, focusing on novel pharmacologic agents and bariatric surgery, and their impact on endometrial cancer risk and outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101929"},"PeriodicalIF":1.3,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of CT-PCI and CA-125 changes following neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A retrospective study from Vietnam","authors":"Ty Van Ngo ,&nbsp;Luc Tien Dao ,&nbsp;Anh Dinh Tran ,&nbsp;Chinh Tri Le ,&nbsp;Hau Xuan Nguyen ,&nbsp;Huyen Thi Phung","doi":"10.1016/j.gore.2025.101927","DOIUrl":"10.1016/j.gore.2025.101927","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to evaluate the prognostic significance of CT-based Peritoneal Cancer Index (CT-PCI) scores and serum CA-125 levels, assessed before and after neoadjuvant chemotherapy (NACT), in relation to surgical outcomes and survival among patients with advanced-stage epithelial ovarian cancer (EOC).</div></div><div><h3>Methods</h3><div>This retrospective study included 96 patients with advanced EOC who received NACT followed by interval debulking surgery (IDS) at Hanoi Medical University Hospital and the National Cancer Hospital (K Hospital), Vietnam, between 2019 and 2024. CT-PCI scores and CA-125 levels were assessed both pre- and post-NACT. The associations between these changes and surgical outcomes, particularly optimal cytoreduction, were analyzed.</div></div><div><h3>Results</h3><div>The mean age was 59.17 years (SD = 9.78), with 94.8 % of patients diagnosed with high-grade serous carcinoma and 51.0 % classified as FIGO stage IIIC. Median CT-PCI scores decreased from 14.0 (IQR: 7.0–19.0) to 4.0 (IQR: 2.0–8.0), and median CA-125 levels declined from 1248 U/ml (IQR: 389–2855) to 31.25 U/ml (IQR: 16.75–147.3) post-treatment (both p &lt; 0.01). Optimal cytoreduction was achieved in 84.4 % of cases. Post-NACT CT-PCI scores and CA-125 levels &gt; 35 U/ml were significantly associated with suboptimal cytoreduction (cOR = 1.15, 95 % CI: 1.03–1.27, p = 0.01; and cOR = 5.26, 95 % CI: 1.38–33.00, p = 0.02, respectively). Median progression-free survival was 20.5 months; median overall survival was 36.7 months.</div></div><div><h3>Conclusion</h3><div>Post-treatment CT-PCI scores and CA-125 levels are valuable prognostic indicators in advanced epithelial ovarian cancer. Their reduction following NACT correlates significantly with improved progression-free and overall survival. These findings support their potential role in informing clinical decision-making and tailoring personalized treatment strategies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101927"},"PeriodicalIF":1.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}